Coya Therapeutics

Home
United States
Houston, TX
Coya Therapeutics

Unleashing the power of Tregs to tackle neurodegenerative and autoimmune diseases. Headquartered in Houston, TX, Coya Therapeutics, Inc.

(Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sust

ained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. Coya’s mission is focused on the advancement of innovative therapeutic approaches to address the significant unmet medical needs of patients with serious neurodegenerative, autoimmune, and metabolic diseases. For more information about Coya, please visit www.coyatherapeutics.com.

07/17/2026

What happens inside the brain after repetitive head impacts, and why has inflammation become such an important focus for researchers?

In this clip from our recent webinar on brain injury, Solomon Wilcots, Leigh Steinberg, and Stanley H. Appel, MD, discuss the biological changes that can occur following repeated head trauma, including how inflammation may disrupt critical neural connections and contribute to neurodegenerative disease. Their conversation underscores why understanding, and ultimately targeting, neuroinflammation is an important area of ongoing research.

Watch the full discussion here: https://bit.ly/4fmukk2

07/15/2026

Understanding the shared biology behind diseases has the potential to reshape how new therapies are developed.

In a recent interview with Pharmaceutical Technology, our CEO Arun Swaminathan, PhD, discusses why targeting and restoring regulatory T-cell ( ) function may have implications across multiple neurodegenerative conditions, not just ALS. By focusing on common underlying disease mechanisms, researchers may be able to develop therapeutic approaches that extend beyond a single indication and address broader unmet needs.

Thank you to Salong Debbarma for the opportunity to discuss the evolving science behind immune modulation in neurodegenerative disease.

Read the article here: https://bit.ly/4wORNSi

07/02/2026

We’re grateful to Solomon Wilcots and Bleav in Bengals for the opportunity to discuss the importance of awareness following the recent diagnosis of former NFL running back Chris Johnson.

In this conversation, our President and CMO Fred Grossman, DO, FAPA, shares insights into the science behind , the urgent need for continued research, and how innovation is advancing the search for new treatment options. The discussion also highlights the important role the football community can play in supporting individuals and families affected by this devastating disease.

Thank you to the Bleav in Bengals team for helping bring greater attention to ALS and the work still ahead.

Listen to the episode here:
https://bleav.com/shows/bleav-in-bengals/episodes/dr-fred-grossman-on-als-research-and-chris-johnsons-diagnosis/

06/26/2026

Our CEO, Arun Swaminathan, PhD, was recently interviewed by Salong Debbarma of Pharmaceutical Technology, discussing the significance of the FDA’s Fast Track Designation for COYA 302 and the path forward for the ALSTARS Phase 2 trial in .

In the conversation, Arun highlights Coya’s focus on restoring regulatory T-cell function and addressing , as well as the company’s priorities for the coming year, including advancing enrollment in ALSTARS, expanding into , and generating additional translational and biomarker data.

Read the article here: https://www.pharmaceutical-technology.com/interviews/coya-therapeutics-ceo-als-coya-302/?cf-view

06/24/2026

Happening TODAY: Don’t miss out on our live webinar, “Beyond the Hit: How Repetitive Head Trauma, Inflammation, and Neurodegenerative Disease Intersect.”

Join Coya and leading experts across sports advocacy, clinical neurology, and therapeutic research for a timely discussion on where the field stands today and where it’s headed next.

🕒 4 PM ET / 1 PM PT
💬 Live Q&A included
🎥 Recording will be available afterward on the Coya website

🔗 Register now: https://russopr.zoom.us/webinar/register/WN_EtIIz8PORk2pLEaM8pgNQQ #/registration

06/23/2026

There’s still time to register for our live webinar on Wednesday, June 24 at 4 PM ET / 1 PM ET!

Join us tomorrow for a timely conversation exploring the relationship between repetitive head trauma, chronic inflammation and neurodegenerative diseases, including and .

The discussion will bring together leaders across sports advocacy, clinical neurology, and therapeutic research to share perspectives on science, patient impact, and the path forward.

🔗 Register Here: https://russopr.zoom.us/webinar/register/WN_EtIIz8PORk2pLEaM8pgNQQ #/registration

06/19/2026

The ALSTARS Phase 2 clinical trial continues to make progress, with participants now advancing into the blinded extension phase of the study.

As the trial moves forward, ALSTARS remains actively enrolling eligible individuals with across participating sites in the United States and Canada.

Learn more about the ALSTARS trial: trials.coyatherapeutics.com

06/15/2026

Coya will host a live webinar, “Beyond the Hit: How Repetitive Head Trauma, Inflammation, and Neurodegenerative Disease Intersect,” on Wednesday, June 24 at 4 PM ET / 1 PM PT.

The webinar will explore the relationship between repetitive head trauma, chronic inflammation, and neurodegenerative diseases, including and , featuring insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg. This discussion will be moderated by NFL broadcaster and former Cincinnati Bengals player Solomon Wilcots.

Register here: https://russopr.zoom.us/webinar/register/WN_EtIIz8PORk2pLEaM8pgNQQ

06/11/2026

Last week, on Lou Gehrig Day, members of the Coya team were proud to join fans across the MLB in honoring Lou Gehrig’s legacy and helping raise awareness for .

Alongside the New York Yankees, Chicago Cubs, and Seattle Mariners, we joined a remarkable network of organizations, including ALS United Greater New York, Her ALS Story, I AM ALS, MAC Angels, Target ALS, Les Turner ALS Foundation, Live Like Lou Foundation, Phi Delta Theta, Permobil Foundation, and ALS United, working to support the ALS community and accelerate progress toward better treatments.

Moments like these are a powerful reminder of the strength of the ALS community across the country, all united by a shared commitment to advancing awareness, research, and hope for everyone affected by ALS.

To learn more about our ALSTARS clinical trial: https://trials.coyatherapeutics.com/

06/09/2026

Progress against takes a team effort.

We’re grateful to former Yankees outfielder Chris Dickerson for lending his voice to help raise awareness of ALS and the ongoing need for research and innovation. His support helps shine a light on the patients, caregivers, clinicians, researchers, and advocates working tirelessly to move the field forward.

Coya is advancing the ALSTARS clinical trial, evaluating COYA 302 as a potential treatment for people living with ALS. Every step forward is made possible by a community united around a common goal: creating a better future for patients and families affected by this disease.

To learn more about our trial: https://trials.coyatherapeutics.com/

Address

Houston, TX

Website

https://coyatherapeutics.com/

Alerts

Be the first to know and let us send you an email when Coya Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Engineering Company in Houston?